A proprietary genetically engineering hepatitis E vaccine, developed by the Xiamen University, was recently approved by the state authorities for I/II clinical trials. The vaccine expects to be the second GE tools preventing hepatitis in the world, following the appearance of hepatitis B vaccine.

The I/II clinical trials will be divided into phase I safety testing, and phase II immunity testing. During the phase I trials, vaccines will be injected into human body for adverse reaction observation. Phase II will test the vaccine safety on an expanded basis, observing antibody formation. It will take some one year to complete the two-phase trails. Researchers will start the Phase III protection trials to observe actual prevention results of the vaccine among more people, if the preceding two trials go smooth.